Related references
Note: Only part of the references are listed.Autologous hematopoietic cell transplantation during second or subsequent complete remission of acute promyelocytic leukemia: a prognostic factor analysis
Masamitsu Yanada et al.
BONE MARROW TRANSPLANTATION (2022)
Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission
Jaime Sanz et al.
BONE MARROW TRANSPLANTATION (2021)
Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens
N. A. Fouzia et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
The evolving concept of indications for allogeneic hematopoietic cell transplantation during first complete remission of acute myeloid leukemia
Masamitsu Yanada
BONE MARROW TRANSPLANTATION (2021)
Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults: 25 years of experience in Japan
Masamitsu Yanada et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2020)
A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide
Uday Kulkarni et al.
CANCER MEDICINE (2020)
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet
Miguel A. Sanz et al.
BLOOD (2019)
Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse
Licia Iaccarino et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan compared with busulfan and cyclophosphamide in high risk patients autografted in first complete remission: A study from the acute leukemia working party of the EBMT
Norbert Claude Gorin et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy
Laura Cicconi et al.
ANNALS OF HEMATOLOGY (2018)
Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial
Nigel Russell et al.
BLOOD (2018)
Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab
Yasmin Abaza et al.
BLOOD (2017)
Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission: outcomes before and after the introduction of arsenic trioxide
Masamitsu Yanada et al.
LEUKEMIA & LYMPHOMA (2017)
Current standard treatment of adult acute promyelocytic leukaemia
Francesco Lo-Coco et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia
Hongming Zhu et al.
BLOOD (2016)
Autologous transplant remains the preferred therapy for relapsed APL in CR2
C. Ganzel et al.
BONE MARROW TRANSPLANTATION (2016)
Changes in Cytogenetics and Molecular Genetics in Acute Myeloid Leukemia From Childhood to Adult Age Groups
Ursula Creutzig et al.
CANCER (2016)
Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients
Yinjun Lou et al.
ANNALS OF HEMATOLOGY (2015)
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide
David Sanford et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial
Alan K. Burnett et al.
LANCET ONCOLOGY (2015)
Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet
E. Lengfelder et al.
LEUKEMIA (2015)
Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission
Jennifer L. Holter Chakrabarty et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Tamibarotene As Maintenance Therapy for Acute Promyelocytic Leukemia: Results From a Randomized Controlled Trial
Katsuji Shinagawa et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Carcinogenic risk of retained arsenic after successful treatment of acute promyelocytic leukemia with arsenic trioxide: a cause for concern?
Frank Firkin
LEUKEMIA & LYMPHOMA (2014)
Resistance to Arsenic Therapy in Acute Promyelocytic Leukemia
Hong-Hu Zhu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia
Masamitsu Yanada et al.
BLOOD (2013)
Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: A retrospective analysis of JALSG-APL97
Hiroyuki Fujita et al.
CANCER SCIENCE (2013)
Outcomes in Patients With Relapsed or Refractory Acute Promyelocytic Leukemia Treated With or Without Autologous or Allogeneic Hematopoietic Stem Cell Transplantation
Naveen Pemmaraju et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in acute promyelocytic leukemia
Akihiro Tomita et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2013)
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
F. Lo-Coco et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)
Harry J. Iland et al.
BLOOD (2012)
Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment
Emi Goto et al.
BLOOD (2011)
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome
Miguel A. Sanz et al.
BLOOD (2010)
Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group
Francesco Lo-Coco et al.
BLOOD (2010)
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
David Grimwade et al.
BLOOD (2010)
Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia
Toru Kiguchi et al.
LEUKEMIA RESEARCH (2010)
Comparison of Clinical Outcomes of Patients with Relapsed Acute Promyelocytic Leukemia Induced with Arsenic Trioxide and Consolidated with Either an Autologous Stem Cell Transplant or an Arsenic Trioxide-Based Regimen
Rajasekar Thirugnanam et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Miguel A. Sanz et al.
BLOOD (2009)
Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis
Pau Montesinos et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Hematopoietic stem cell transplantation for acute promyelocytic leukemia in second or third complete remission: a retrospective analysis in the Nagoya Blood and Marrow Transplantation Group
Akio Kohno et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2008)
Arsenic-induced APL differentiation in cerebrospinal fluid
Annett Helwig et al.
LEUKEMIA RESEARCH (2007)
Is cytarabine useful in the treatment of acute promyelocytic leukemia?: Results of a randomized trial from the European Acute Promyelocytic Leukemia Group
Lionel AdeS et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: Updated outcomes of the phase II study and postremission therapies
K Shigeno et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2005)
Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells
A Takeshita et al.
LEUKEMIA (2005)
Arsenic trioxide: New clinical experience with an old medication in hematologic malignancies
D Douer et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: A retrospective analysis of the European acute promyelocytic leukemia group
S de Botton et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia
F Lo-Coco et al.
BLOOD (2004)
Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia
E Raffoux et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia
SL Soignet et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
